These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35272009)

  • 1. Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
    Tian C; Huang S; Xu Z; Liu W; Li D; Liu M; Zhu C; Wu L; Jiang X; Ding H; Zhao Q
    Bioorg Med Chem Lett; 2022 May; 64():128663. PubMed ID: 35272009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
    Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
    Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
    Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
    Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
    Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
    Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of thiadiazolo-carboxamide bridged β-carboline-indole hybrids: DNA intercalative topo-IIα inhibition with promising antiproliferative activity.
    Tokala R; Sana S; Lakshmi UJ; Sankarana P; Sigalapalli DK; Gadewal N; Kode J; Shankaraiah N
    Bioorg Chem; 2020 Dec; 105():104357. PubMed ID: 33091673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities.
    Ling Y; Feng J; Luo L; Guo J; Peng Y; Wang T; Ge X; Xu Q; Wang X; Dai H; Zhang Y
    ChemMedChem; 2017 May; 12(9):646-651. PubMed ID: 28425177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
    Ling Y; Gao WJ; Ling C; Liu J; Meng C; Qian J; Liu S; Gan H; Wu H; Tao J; Dai H; Zhang Y
    Eur J Med Chem; 2019 Apr; 168():515-526. PubMed ID: 30851694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
    Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of β-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase IIα inhibition and apoptosis induction.
    Tokala R; Mahajan S; Kiranmai G; Sigalapalli DK; Sana S; John SE; Nagesh N; Shankaraiah N
    Bioorg Chem; 2021 Jan; 106():104481. PubMed ID: 33261848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of some β-carboline derivatives as multi-target anticancer agents.
    Abdelsalam MA; AboulWafa OM; Badawey EA; El-Shoukrofy MS; El-Miligy MM; Gouda N
    Future Med Chem; 2018 Dec; 10(24):2791-2814. PubMed ID: 30539666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.